Bifidobacterium longum promotes postoperative liver function recovery in patients with hepatocellular carcinoma
This study is constructed by three cohorts which approved by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan China). First, a retrospective cohort study (490 patients) was designed and implemented to investigate the prognostic impact of postoperative liver function recovery. Second, a prospective observational cohort study (123 patients, ClinicalTrials number: NCT04303286) was conducted to identify key gut microbial species associated with postoperative liver function recovery. Finally, an open, randomized, blank controlled clinical trial (176 patients, ClinicalTrials.gov identifier: NCT05178524) was performed to test whether a key gut microbial species that was enriched in the normal recovery group compared with the delayed recovery group (i.e., Bifidobacterium longum) can promote the postoperative liver function recovery in HCC patients. At the same time, the effectiveness and mechanism of B. longum on postoperative liver function recovery were verified by using a liver- hepatectomy mouse model. These databases including original western blot images and metabolic data (related to Figures 6 and 7).